Pomerantz LLP Files Class Action Litigation Against AeroVironment, Inc. – AVAV

AeroVironment (AVAV) is facing a securities class action (26-cv-01429) alleging materially false statements about SCAR program prospects amid evolving U.S. Space Force actions. The stock dropped sharply after multiple SCAR-related setbacks—down 15.77% on Jan. 20, 2026 and 17.42% on Mar. 2—then declined another 6.24% after Q3 FY2026 results that included a $179.0M operating loss and a $151.3M goodwill impairment tied to the BADGER stop-work order. The litigation centers on claims that investors were misled about competition and financial outlook for the SCAR program.

Analysis

The lawsuit itself is mostly noise; the investable issue is that a once-visible program has likely shifted from quasi-annuity to competitive re-bid, which is a much bigger valuation problem for AVAV than any eventual legal settlement. For a company priced on growth optionality, the market tends to punish the loss of procurement visibility by compressing EV/sales and assigning a lower probability to follow-on wins, especially when the customer is explicitly moving toward cheaper, multi-vendor solutions.

Second-order winners are the broader defense names with diversified backlog and companies exposed to off-the-shelf subsystems rather than bespoke sole-source awards. That argues for relative value in KTOS and LHX versus AVAV, and possibly a mild tailwind to defense ETFs like XAR as capital rotates away from single-program concentration risk. The supply-chain implication is that AVAV’s ecosystem may face slower orders, while component and integration suppliers with multiple end markets are insulated.

Near term, litigation headlines can keep implied vol elevated, but the real catalyst path is the Space Force acquisition strategy over the next 1-3 months. If the recompete is broadened, AVAV’s FY27 revenue bridge likely needs a reset; if it stays focused or bridge funding is announced, the short thesis weakens quickly. Over 6-18 months, the structural risk is a lower recurring revenue base and a more skeptical multiple for any defense-tech name that depends on one bespoke government platform.

The contrarian view is that the market may already have discounted most of the bad news after the stop-work and termination events, so an outright short here is less attractive than a pair trade. The key missing data is how much of AVAV’s remaining space segment growth plan was actually dependent on SCAR; without that, the legal overhang could be overtrading relative to the fundamental hit.

Key Decisions for Investors

• Prefer a relative-value short AVAV / long KTOS or LHX over the next 1-3 months; the thesis is procurement diversification hurts single-program concentration while diversified defense platforms preserve backlog visibility.
• If AVAV rallies on litigation chatter, use it to initiate a 3-6 month bearish options structure such as an AVAV put spread rather than outright stock shorting; risk/reward improves if the market is temporarily ignoring the program-reset issue.
• Do not chase a broad defense short; use XAR or LHX as a hedge if carrying AVAV short exposure, since the issue is company-specific program concentration, not sector demand.
• Set a hard cover alert if the Space Force awards AVAV a meaningful bridge/limited-scope extension or if management quantifies limited FY27 revenue impact; that would falsify the de-rating thesis.
• Watch for estimate cuts into the next earnings cycle; if sell-side consensus does not reflect a lower SCAR contribution by then, the stock may have another leg down as models catch up.